PacBio publishes 2025 annual report

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.

PACB

0.00
  • PacBio annual report for fiscal 2025 highlighted rising adoption of HiFi long-read sequencing across rare disease, oncology, AI-driven biology, and population-scale genomics.
  • Revio and Vega utilization increased, shifting growth mix toward higher recurring consumables sales.
  • Platform roadmap centered on SPRQ-Nx chemistry and SMRT Cell Nx to lift output per SMRT Cell, lower cost per genome, and support higher-throughput workflows.
  • Partnerships with Covaris targeted improved HiFi sequencing from FFPE tumor samples; Basecamp Research collaboration positioned HiFi datasets for AI model development.
  • PacBio completed sale of short-read sequencing assets to sharpen focus on HiFi long-read sequencing; 2026 priorities emphasized clinical expansion and sequencing economics improvements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.